Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease
- PMID: 2788466
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease
Abstract
Castleman's disease is a syndrome consisting of giant lymph node hyperplasia with plasma cell infiltration, fever, anemia, hypergammaglobulinemia, and an increase in the plasma level of acute phase proteins. It has been reported that clinical abnormalities disappear after the resection of the affected lymph nodes, suggesting that products of lymph nodes may cause such clinical abnormalities. Interleukin-6 (IL-6) is a cytokine inducing B-cell differentiation to immunoglobulin-producing cells and regulating biosynthesis of acute phase proteins. This report demonstrates that the germinal centers of hyperplastic lymph nodes of patients with Castleman's disease produce large quantities of IL-6 without any significant production of other cytokines. In a patient with a solitary hyperplastic lymph node, clinical improvement and decrease in serum IL-6 were observed following surgical removal of the involved lymph node. There was a correlation between serum IL-6 level, lymph node hyperplasia, hypergammaglobulinemia, increased level of acute phase proteins, and clinical abnormalities. The findings in this report indicate that the generation of IL-6 by B cells in germinal centers of hyperplastic lymph nodes of Castleman's disease may be the key element responsible for the variety of clinical symptoms in this disease.
Similar articles
-
Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.Leuk Lymphoma. 2000 Jul;38(3-4):387-94. doi: 10.3109/10428190009087030. Leuk Lymphoma. 2000. PMID: 10830746 Review.
-
[Clinical significance of cytokines-interleukin 6 in disease].Rinsho Byori. 1990 Apr;38(4):375-9. Rinsho Byori. 1990. PMID: 2366383 Japanese.
-
Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease.Mod Pathol. 2009 Apr;22(4):589-99. doi: 10.1038/modpathol.2009.17. Epub 2009 Mar 6. Mod Pathol. 2009. PMID: 19270642
-
Interleukin-6 gene expression in Castleman's disease.Blood. 1991 Dec 1;78(11):2923-30. Blood. 1991. PMID: 1954381
-
Neonatal giant lymph node hyperplasia (Castleman's disease) presenting in the head and neck.Br J Oral Maxillofac Surg. 1991 Apr;29(2):110-1. doi: 10.1016/0266-4356(91)90094-l. Br J Oral Maxillofac Surg. 1991. PMID: 2049350 Review.
Cited by
-
Spatial and Single Cell Mapping of Castleman Disease Reveals Key Stromal Cell Types and Cytokine Pathways.bioRxiv [Preprint]. 2024 Sep 9:2024.09.09.609717. doi: 10.1101/2024.09.09.609717. bioRxiv. 2024. Update in: Nat Commun. 2025 Jul 1;16(1):6009. doi: 10.1038/s41467-025-61214-1. PMID: 39314418 Free PMC article. Updated. Preprint.
-
Castleman disease in the parapharyngeal space: a case report and review of the literature.Head Neck Pathol. 2013 Dec;7(4):389-92. doi: 10.1007/s12105-013-0449-9. Epub 2013 May 16. Head Neck Pathol. 2013. PMID: 23677703 Free PMC article. Review.
-
A rare case of hyaline-type Castleman disease in the liver.World J Hepatol. 2013 Jul 27;5(7):404-8. doi: 10.4254/wjh.v5.i7.404. World J Hepatol. 2013. PMID: 23898375 Free PMC article.
-
Novel genetically-humanized mouse model established to evaluate efficacy of therapeutic agents to human interleukin-6 receptor.Sci Rep. 2013;3:1196. doi: 10.1038/srep01196. Epub 2013 Feb 1. Sci Rep. 2013. PMID: 23378927 Free PMC article.
-
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4. Blood. 2018. PMID: 30181172 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical